HEMATOPOIETIC CELL TRANSPLANTATION FOR JUVENILE MYELOMONOCYTIC LEUKEMIA AND OTHER MYELOPROLIFERATIVE NEOPLASMS

Neysimelia Costa Villela; Anita Frisanco Oliveira; Rafaela de Souza Ferreira; Gustavo Zamperlini; Andréia Cristina Fortes Bassani; Mariana Bohns Michalowski; Maria Lúcia de Martino Lee

doi:10.46765/2675-374X.2025v6n1e290

HEMATOPOIETIC CELL TRANSPLANTATION FOR JUVENILE MYELOMONOCYTIC LEUKEMIA AND OTHER MYELOPROLIFERATIVE NEOPLASMS

Authors

Neysimelia Costa Villela Hospital de Câncer de Barretos – Barretos (SP), Brazil. https://orcid.org/0000-0002-1435-6820
Anita Frisanco Oliveira Hospital de Câncer de Barretos – Barretos (SP), Brazil. https://orcid.org/0000-0003-2681-9359
Rafaela de Souza Ferreira Hospital de Câncer de Barretos – Barretos (SP), Brazil. https://orcid.org/0009-0002-3474-9928
Gustavo Zamperlini Centro Infantil Boldrini – Campinas (SP), Brazil. https://orcid.org/0009-0002-9007-7652
Andréia Cristina Fortes Bassani Hospital Unimed – Volta Redonda (RJ), Brazil. https://orcid.org/0009-0005-8906-7969
Mariana Bohns Michalowski Hospital de Clínicas de Porto Alegre – Porto Alegre (RS), Brazil|Universidade Federal do Rio Grande do Sul – Porto Alegre (RS), Brazil. https://orcid.org/0000-0002-9482-0776
Maria Lúcia de Martino Lee Beneficência Portuguesa de São Paulo – São Paulo (SP), Brazil. https://orcid.org/0009-0000-0464-7969

DOI:

https://doi.org/10.46765/2675-374X.2025v6n1e290

Keywords:

Leukemia, Myelomonocytic, Juvenile, Hematopoietic Stem Cell Transplantation, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis, Child

Abstract

Juvenile myelomonocytic leukemia (JMML) is a rare and distinctive hematologic neoplasm affecting infants and younger children. Hyperactivation of the RAS signaling pathway is a central initiating event in JMML, which also delineates its various genetic and clinical subtypes. While a small percentage of children may achieve spontaneous clinical remission, allogeneic hematopoietic cell transplantation (HCT) remains the only possible cure for most JMML patients. In this article, we reviewed the indications of HCT in JMML. Other myeloproliferative diseases, such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are extremely rare in pediatrics and are briefly discussed.

References

1. Aricó M, Biondi A, Pui C-H. Juvenile myelomonocytic leukemia. Blood. 1997;90(2):479–88. DOI: https://doi.org/10.1182/blood.V90.2.479.479_479_488

2. Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood J. 2015;125(7):1083–90. https://doi.org/10.1182/blood-2014-08-550483 DOI: https://doi.org/10.1182/blood-2014-08-550483

3. Hasle H, Niemeyer C, Chessells J, Baumann I, Bennett JM, Kerndrup G, Head DR. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277–82. https://doi.org/10.1038/sj.leu.2402765 DOI: https://doi.org/10.1038/sj.leu.2402765

4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544 DOI: https://doi.org/10.1182/blood-2016-03-643544

5. Rudelius M, Weinberg OK, Niemeyer CM, Shimamura A, Calvo KR. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia. Virchows Arch. 2023;482(1):113–30. https://doi.org/10.1007/s00428-022-03447-9 DOI: https://doi.org/10.1007/s00428-022-03447-9

6. Locatelli F, Algeri M, Merli P, Strocchio L. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. Expert Rev Hematol. 2018;11(2):129–43. https://doi.org/10.1080/17474086.2018.1421937 DOI: https://doi.org/10.1080/17474086.2018.1421937

7. Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen S, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber T, Golub T, Stegmaier K, Loh ML. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015; 47(11): 1326–33. https://doi.org/10.1038/ng.3400 DOI: https://doi.org/10.1038/ng.3400

8. Wintering A, Dvorak CC, Stieglitz E, Loh ML. Juvenile myelomonocytic leukemia in the molecular era: a clinician’s guide to diagnosis, risk stratification, and treatment. Blood Adv. 2021;5(22):4783–93. https://doi.org/10.1182/bloodadvances.2021005117 DOI: https://doi.org/10.1182/bloodadvances.2021005117

9. Mayerhofer C, Niemeyer CM, Flotho C. Current treatment of juvenile myelomonocytic leukemia. J Clin Med. 2021;10(14):3084. https://doi.org/10.3390/jcm10143084 DOI: https://doi.org/10.3390/jcm10143084

10. Schönung M, Meyer J, Nöllke P, Olshen AB, Hartmann M, Murakami N, Wakamatsu M, Okuno Y, Plass C, Loh ML, Niemeyer CM, Muramatsu H, Flotho C, Stieglitz E, Lipka DB. International Consensus Definition of DNA methylation subgroups in juvenile myelomonocytic leukemia. Clin Cancer Res. 2021; 27(1): 158–68. https://doi.org/10.1158/1078-0432.ccr-20-3184 DOI: https://doi.org/10.1158/1078-0432.CCR-20-3184

11. Bergstraesser E, Hasle H, Rogge T, Fischer A, Zimmermann M, Noellke P, Niemeyer CM. Non hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer. 2007; 49(5): 629–33. https://doi.org/10.1002/pbc.21038 DOI: https://doi.org/10.1002/pbc.21038

12. Hecht A, Meyer J, Chehab FF, White KL, Magruder K, Dvorak CC, Loh ML, Stieglitz E. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2019; 66(11): e27948. https://doi.org/10.1002/pbc.27948 DOI: https://doi.org/10.1002/pbc.27948

13. Furlan I, Batz C, Flotho C, Mohr B, Lübbert M, Suttorp M, Niemeyer CM. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009; 113(12): 2867–8. https://doi.org/10.1182/blood-2008-12-195693 DOI: https://doi.org/10.1182/blood-2008-12-195693

14. Cseh A, Niemeyer CM, Yoshimi A, Dworzak M, Hasle H, van den Heuvel-Eibrink MM, Locatelli F, Masetti R, Schmugge M, Groß-Wieltsch U, Candás A, Kulozik AE, Olcay L, Suttorp M, Furlan I, Strahm B, Flotho C. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood. 2015; 125(14): 2311–3. https://doi.org/10.1182/blood-2015-01-619734 DOI: https://doi.org/10.1182/blood-2015-01-619734

15. Krombholz CF, Gallego-Villar L, Sahoo SS, Panda PK, Wlodarski MW, Aumann K, Hartmann M, Lipka DB, Daskalakis M, Plass C, Niemeyer CM, Erlacher M, Flotho C. Azacitidine is effective for targeting leukemiainitiating cells in juvenile myelomonocytic leukemia. Leukemia. 2019; 33(7): 1805–10. https://doi.org/10.1038/s41375-018-0343-2 DOI: https://doi.org/10.1038/s41375-018-0343-2

16. Cai Y, Zhang J, Yi M, Zhang W, Liu X, Zhang X, Wan Y, Chang L, Zhang L, Chen X, Guo Y, Zou Y, Chen Y, Li J, Zhang Y, Yang W, Zhu X. Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in China. Int J Hematol. 2023; 117(1): 121–7. https://doi.org/10.1007/s12185-022-03457-y DOI: https://doi.org/10.1007/s12185-022-03457-y

17. Peng Z, Gao J, Huang L, He Y, Tang H, Zong S, Pei Y, Pei F, Ge J, Liu X, Yue L, Zhou J, Li X, Yue D, Chen Y, Chen C, Wu X, Feng X, Li C. Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study. Front Immunol. 2024; 15: 1426640. https://doi.org/10.3389/fimmu.2024.1426640 DOI: https://doi.org/10.3389/fimmu.2024.1426640

18. Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021;5(14):2901–8. https://doi.org/10.1182/bloodadvances.2020004144 DOI: https://doi.org/10.1182/bloodadvances.2020004144

19. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol. 2011;152(6):677–87. https://doi.org/10.1111/j.1365-2141.2010.08525.x DOI: https://doi.org/10.1111/j.1365-2141.2010.08525.x

20. Niemeyer CM. JMML genomics and decisions. Hematology Am Soc Hematol Educ Program. 2018;2018(1):307–12. https://doi.org/10.1182/asheducation-2018.1.307 DOI: https://doi.org/10.1182/asheducation-2018.1.307

21. Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, Olshen A, Hechmer A, Aftandilian C, Bhat R, Choi SW, Chonat S, Farrar JE, Fluchel M, Frangoul H, Han JH, Kolb EA, Kuo DJ, MacMillan ML, Maese L, Maloney KW, Narendran A, Oshrine B, Schultz KR, Sulis ML, Van Mater D, Tasian SK, Hofmann WK, Loh ML, Stieglitz E. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica. 2022;107(1):178–86. https://doi.org/10.3324/haematol.2020.270595 DOI: https://doi.org/10.3324/haematol.2020.270595

22. Yoshida T, Muramatsu H, Wakamatsu M, Sajiki D, Murakami N, Kitazawa H, Okamoto Y, Taniguchi R, Kataoka S, Narita A, Hama A, Okuno Y, Takahashi Y. Clinical and molecular features of CBL-mutated juvenile myelomonocytic leukemia. Haematologica. 2023; 108(11): 3115–9. https://doi.org/10.3324/haematol.2022.282385 DOI: https://doi.org/10.3324/haematol.2022.282385

23. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo C, Bonfim CS, Bader P, Dilloo D, Stary J, Fischer A, Révész T, Führer M, Hasle H, Trebo M, van den Heuvel-Eibrink MM, Fenu S, Strahm B, Giorgiani G, Bonora MR, Duffner U, Niemeyer CM; European Working Group on Childhood MDS; European Blood and Marrow Transplantation Group. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOGMDS/EBMT trial. Blood. 2005;105(1):410–9. https://doi.org/10.1182/blood-2004-05-1944 DOI: https://doi.org/10.1182/blood-2004-05-1944

24. Sakashita K, Yoshida N, Muramatsu H, Ohtsuka Y, Watanabe K, Yabe M, Kakuda H, Honda Y, Watanabe T, Haba M, Ohmori S, Matsuda K, Yuza Y, Saito A, Horibe K, Adachi S, Manabe A. Allogeneic hematopoietic cell transplantation for juvenile myelomonocytic leukemia with a busulfan, fludarabine, and melphalan regimen: JPLSG JMML-11. Transplant Cell Ther. 2024;30(1):105.e1–e10. https://doi.org/10.1016/j.jtct.2023.10.002 DOI: https://doi.org/10.1016/j.jtct.2023.10.002

25. SmithFO, King R, Nelson G, Wagner JE, Robertson KA, Sanders JE, BuninN, Emaunel PD, Davies SM; NationalMarrow Donor Program. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol. 2002;116(3):716–24. https://doi.org/10.1046/j.0007-1048.2001.03333.x DOI: https://doi.org/10.1046/j.0007-1048.2001.03333.x

26. Locatelli F, Crotta A, Ruggeri A, Eapen M, Wagner JE, Macmillan ML, Zecca M, Kurtzberg J, Bonfim C, Vora A, Díaz de Heredia C, Teague L, Stein J, O’Brien TA, Bittencourt H, Madureira A, Strahm B, Peters C, Niemeyer C, Gluckman E, Rocha V. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood. 2013;122(12):2135–41. https://doi.org/10.1182/blood-2013-03-491589 DOI: https://doi.org/10.1182/blood-2013-03-491589

27. Kalwak K, Wójcik D, Gorczyńska E, Toporski J, Turkiewicz D, Slociak M, Ussowicz M, Pajdosz K, Socha P, Chybicka A. Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative? Transplant Proc. 2004;36(5):1574–7. https://doi.org/10.1016/j.transproceed.2004.05.081 DOI: https://doi.org/10.1016/j.transproceed.2004.05.081

28. Trujillo ÁM, Karduss AJ, Suarez G, Pérez R, Ruiz G, Cardona A, Ramírez M, Betancur J. Haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide in children with high-risk leukemia using a reduced-intensity conditioning regimen and peripheral blood as the stem cell source. Transplant Cell Ther. 2021;27(5):427.e1–e7. https://doi.org/10.1016/j.jtct.2021.02.010 DOI: https://doi.org/10.1016/j.jtct.2021.02.010

29. Ding L, Zhu H, Han DM, Wang ZD, Zheng XL, Dong L, Yan HM, Liu J, Zhu L, Xue M, Guo ZK, Wang HX [Clinical study on treatment of juvenile myelomonocytic leukemia with haploidentical-hematopoietic stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25(5):1524–7. https://doi.org/10.7534/j.issn.1009-2137.2017.05.043

30. Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, Gao Y, Wall D, Mazor T, Olshen AB, Parker JS, Kahwash S, Hirsch B, Raimondi S, Patel N, Skeens M, Cooper T, Mehta PA, Grupp SA, Loh ML. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children’s Oncology Group study. Pediatr Blood Cancer. 2018;65(7):e27034. https://doi.org/10.1002/pbc.27034 DOI: https://doi.org/10.1002/pbc.27034

31. Matthes-Martin S, Mann G, Peters C, Lion T, Fritsch G, Haas OA, Pötschger U, Gadner H. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. Bone Marrow Transplant. 2000;26(4):377–82. https://doi.org/10.1038/sj.bmt.1702522

32. Manabe A, Okamura J, Yumura-Yagi K, Akiyama Y, Sako M, Uchiyama H, Kojima S, Koike K, Saito T, Nakahata T; MDS Committee of the Japanese Society of Pediatric Hematology. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia. 2002;16(4):645–9. https://doi.org/10.1038/sj.leu.2402407 DOI: https://doi.org/10.1038/sj.leu.2402407

33. Matthes-Martin S, Mann G, Peters C, Lion T, Fritsch G, Haas OA, Pötschger U, Gadner H. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. Bone Marrow Transplant. 2000;26(4):377–82. https://doi.org/10.1038/sj.bmt.1702522 DOI: https://doi.org/10.1038/sj.bmt.1702522

34. Vinci L, Flotho C, Noellke P, Lebrecht D, Masetti R, de Haas V, De Moerloose B, Dworzak M, Hasle H, Güngör T, Starý J, Turkiewicz D, Ussowicz M, de Heredia CD, Buechner J, Jahnukainen K, Kallay K, Bodova I, Smith OP, Zecca M, Bresters D, Lang P, Masmas TN, Meisel R, Pichler H, Erlacher M, Göhring G, Locatelli F, Strahm B, Niemeyer CM, Yoshimi A. Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft. Bone Marrow Transplant. 2023;58(5):607–9. https://doi.org/10.1038/s41409-023-01942-4 DOI: https://doi.org/10.1038/s41409-023-01942-4

35. Chang Y-H, Jou S-T, Lin D-T, Lu M-Y, Lin K-H. Second allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia: case report and literature review. J Pediatr Hematol Oncol. 2004; 26(3):190–3. https://doi.org/10.1097/00043426-200403000-00009 DOI: https://doi.org/10.1097/00043426-200403000-00009

36. Meyran D, Arfeuille C, Chevret S, Neven Q, Caye-Eude A, Lainey E, Petit A, Rialland F, Michel G, Plantaz D, Jubert C, Theron A, Gandemer V, Ouachée-Chardin M, Paillard C, Bruno B, Buchbinder N, Pochon C, Calvo C, Fahd M, Baruchel A, Cavé H, Dalle JH, Strullu M. A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Haematologica. 2024;109(9):2908–19. https://doi.org/10.3324/haematol.2023.284103 DOI: https://doi.org/10.3324/haematol.2023.284103

37. Yoshimi A, Niemeyer CM, Bohmer V, Duffner U, Strahm B, Kreyenberg H, Dilloo D, Zintl F, Claviez A, Wössmann W, Kremens B, Holter W, Niethammer D, Beck JF, Kontny U, Nöllke P, Klingebiel T, Bader P. Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. Br J Haematol. 2005;129(4):542–9. https://doi.org/10.1111/j.1365-2141.2005.05489.x DOI: https://doi.org/10.1111/j.1365-2141.2005.05489.x

38. Inagaki J, Fukano R, Nishikawa T, Nakashima K, Sawa D, Ito N, Okamura J. Outcomes of immunological interventions for mixed chimerism following allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2013;60(1):116–20. https://doi.org/10.1002/pbc.24259 DOI: https://doi.org/10.1002/pbc.24259

39. Stieglitz E, Lee AG, Angus SP, Davis C, Barkauskas DA, Hall D, Kogan SC, Meyer J, Rhodes SD, Tasian SK, Xuei X, Shannon K, Loh ML, Fox E, Weigel BJ. Efficacy of the allosteric MEK inhibitor trametinib in relapsed and refractory juvenile myelomonocytic leukemia: a report from the Children’s Oncology Group. Cancer Discov. 2024;14(9):1590–8. https://doi.org/10.1158/2159-8290.CD-23-1376 DOI: https://doi.org/10.1158/2159-8290.CD-23-1376

40. Hofmann I. Myeloproliferative neoplasms in children. J Hematop. 2015;8(3):143–57. https://doi.org/10.1007/s12308-015-0256-1 DOI: https://doi.org/10.1007/s12308-015-0256-1

41. Kucine N. Myeloproliferative neoplasms in children, adolescents, and young adults. Curr Hematol Malig Rep. 2020;15(2):141–8. https://doi.org/10.1007/s11899-020-00571-8 DOI: https://doi.org/10.1007/s11899-020-00571-8

42. Sobas M, Ianotto JC, Kiladjian JJ, Harrison C. Myeloproliferative neoplasms: young patients, current data and future considerations. Ann Hematol. 2024;103(9):3287–91. https://doi.org/10.1007/s00277-024-05920-8 DOI: https://doi.org/10.1007/s00277-024-05920-8

43. Sobas M, Kiladjian JJ, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih LY, Devos T, Krochmalczyk D, Galli S, Bieniaszewska M, Seferynska I, McMullin MF, Armatys A, Spalek A, Waclaw J, Zdrenghea M, Legros L, Girodon F, Lewandowski K, Angona Figueras A, Samuelsson J, Abuin Blanco A, Cony-Makhoul P, Collins A, James C, Kusec R, Lauermannova M, Noya MS, Skowronek M, Szukalski L, Szmigielska-Kaplon A, Wondergem M, Dudchenko I, Gora Tybor J, Laribi K, Kulikowska de Nalecz A, Demory JL, Le Du K, Zweegman S, Besses Raebel C, Skoda R, Giraudier S, Griesshammer M, Harrison CN, Ianotto JC. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022;6(17):5171–83. https://doi.org/10.1182/bloodadvances.2022007201 DOI: https://doi.org/10.1182/bloodadvances.2022007201

44. Wachowiak J, Galimard JE, Dalissier A, Rihani R, AlSaedi H, Wynn RF, Dalle JH, Peffault de Latour R,

Sedlacek P, Balduzzi A, Schroeder T, Bodova I, Gonzalez Vicent M, Gruhn B, Hamladji RM, Krivan G, Patrick K, Sobkowiak-Sobierajska A, Stepensky P, Unal A, Amrolia P, Perez Martinez A, Rialland F, Aljurf M, Isgro A, Toren A, Bierings M, Corbacioglu S, Kałwak K. Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP. Bone Marrow Transplant. 2024;59(8):1057–69. https://doi.org/10.1038/s41409-024-02286-3 DOI: https://doi.org/10.1038/s41409-024-02286-3

45. Putti MC, Bertozzi I, Randi ML. Essential thrombocythemia in children and adolescents. Cancers (Basel). 2021;13(23):6147. https://doi.org/10.3390/cancers13236147 DOI: https://doi.org/10.3390/cancers13236147

46. Picard A, Bayart S, Deparis M, De Maricourt CD, Haro S, Jourdain A, Mallebranche C, Rialland F, Luque Paz D, Pastoret C, Gandemer V, Cousin E. Polycythemia vera and essential thrombocythemia in children, still a challenge for pediatricians. Eur J Pediatr. 2025;184(2):173. https://doi.org/10.1007/s00431-025-05993-1 DOI: https://doi.org/10.1007/s00431-025-05993-1

Downloads

Published

11/30/2025

How to Cite

Villela, N. C., Oliveira, A. F., Ferreira, R. de S., Zamperlini, G., Bassani, A. C. F., Michalowski, M. B., & Lee, M. L. de M. (2025). HEMATOPOIETIC CELL TRANSPLANTATION FOR JUVENILE MYELOMONOCYTIC LEUKEMIA AND OTHER MYELOPROLIFERATIVE NEOPLASMS. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 6(1). https://doi.org/10.46765/2675-374X.2025v6n1e290

Download Citation

Issue

Vol. 6 No. 1 (2025): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Pediatric Consensus Updates

License

Copyright (c) 2025 Neysimelia Costa Villela, Anita Frisanco Oliveira, Rafaela de Souza Ferreira, Gustavo Zamperlini, Andréia Cristina Fortes Bassani, Mariana Bohns Michalowski, Maria Lúcia de Martino Lee

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

Adriana Seber, Alessandra Gomes, Ana Karine Vieira, Ana Luiza Melo Rodrigues, Ana Maria Marinho da Silva, Antonella Zanette, Antonio Vaz de Macedo, Carla Nolasco Monteiro Breviglieri, Carla Zanchetta, Carmem Bonfim, Cilmara Kuwahara, Cinthya Rocha Carvalho, Cláudio Galvão de Castro Junior, Fernanda Lima Lelis, Gabriele Zamperlini Netto, Gustavo Zamperlini, Julia Lopes Garcia, Juliana Folloni Fernandes, Karoline Helena Silva da Silva, Laila Rigolin Fortunato, Lauro José Gregianin, Liane Esteves Daudt, Luciana Domingues, Luiz Guilherme Darrigo Junior, Maria Gabriela Matos, Maria Lucia Lee, Mariana Bohns Michalowski, Maura Ikoma-Colturato, Monica Cypriano, Natália Maria Tavares Ferreira Borges, Neysimelia Costa Villela, Paola Soriano, Patrícia Shimoda Ikeuti, Paulo Henrique dos Santos Klinger, Raul Ribeiro, Renata Fittipaldi Guimaraes, Rita Barbosa Tavares, Roseane Gouveia, Samantha Nichele, Simone de Castro Resende Franco, Valeria Cortez Ginani, Victor Gottardello Zecchin, Virginio Fernandes, HSCT FOR PEDIATRIC DISEASES , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 2 No. 1 (2021): Journal of Bone Marrow Transplantation and Cellular Therapy
Carla Nolasco Monteiro Breviglieri, Mariana Bohns Michalowski , Lauro Gregianin, Claudio Galvão Castro Júnior, Hematopoietic stem cell transplantation for neuroblastoma , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 2 No. 4 (2021): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Cilmara Kuwahara, Gabriele Zamperlini Neto, Mariana Bohns Michalowski , Valéria Cortez Ginani, Carla Nolasco Monteiro Breviglieri, HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC LYMPHOMAS , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 2 No. 4 (2021): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Polliany Roberta Dorini Pelegrina, Roseane Vasconcelos Gouveia , Antonio Vaz de Macedo, Ana Karine Vieira, Gabriela Gaspar Filgueiras Landi, Julia Lopes, Osvaldo Alves de Menezes Neto, Rafaela de Souza Ferreira, Adriana Aparecida Siviero Miachon, Rita de Cássia Barbosa da Silva Tavares , Carmem Bonfim, Long-term follow-up after pediatric hematopoietic stem cell transplantation , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 6 No. 1 (2025): Journal of Bone Marrow Transplantation and Cellular Therapy
Rita de Cássia Barbosa Tavares, Polliany Roberta Dorini Pelegrina, Carla Nolasco Monteiro Breviglieri, Ana Luiza de Mello Rodrigues, Gustavo Zamperlini, Adriana Martins de Sousa, Patricia Regina Cavalcanti Barbosa Horn, Luiz Guilherme Darrigo Jr, Liane Daudt, Management of pediatric acute leukemias relapse after hematopoietic cell transplantation , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 6 No. 1 (2025): Journal of Bone Marrow Transplantation and Cellular Therapy
Neysimelia Costa Villela, Patrícia Shimoda Ikeuti, Simone de Castro Resende Franco, Roseane Vasconcelos Gouveia, Gustavo Zamperlini, Luiz Fernando Lopes, Myelodysplastic syndromes (MDS) , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 2 No. 4 (2021): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Victor Gottardello Zecchin, MONICA DOS SANTOS CYPRIANO, GUSTAVO ZAMPERLINI, Conditioning Regimen For Langerhans Histiocytosis , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 2 No. 4 (2021): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Neysimelia Costa Villela, Roseane Vasconcelos Gouveia, Simone de Castro Resende Franco, Gustavo Zamperlini, Patrícia Shimoda Ikeuti, Luiz Fernando Lopes, Juvenile Myelomonocytic Leukemia and other myelodysplastic/myeloproliferative neoplasms , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 2 No. 4 (2021): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Neysimelia Costa Villela, Gustavo Zamperlini, Patrícia Shimoda Ikeuti, Roseane Vasconcelos Gouveia, Simone de Castro Resende Franco, Luiz Fernando Lopes, Myeloproliferative neoplasms , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 2 No. 4 (2021): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Gustavo Zamperlini, Paulo Henrique dos Santos Klinger, Antonella Zanette, Cilmara Kuwahara, Sidnei Epelman, Adriana Seber, Cláudio Galvão de Castro Junior, Central nervous system tumors , JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY: Vol. 6 No. 1 (2025): Journal of Bone Marrow Transplantation and Cellular Therapy

1 2 > >>

HEMATOPOIETIC CELL TRANSPLANTATION FOR JUVENILE MYELOMONOCYTIC LEUKEMIA AND OTHER MYELOPROLIFERATIVE NEOPLASMS

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License

Most read articles by the same author(s)

Similar Articles

Make a Submission

Keywords

Index

Information